Neurocrine Biosciences shows strong growth with rising INGREZZA sales, expanding pipeline, and solid financials despite key ...
PRESS RELEASE Paris, 17th October 2025 Annual results at the end of June 2025Revenue growth of 4.7% and Group EBITDA up 1.7% despite reduction in public funding; secured long ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback